Search results for "CCR5"

showing 10 items of 20 documents

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

2018

The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of C-C chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. A randomized, double-blind, multinational phase 2b study enrolled subjects with NASH, a nonalcoholic fatty liver disease activity score [NAS] ≥4, and liver fibrosis (stages 1-3, NASH Clinical Research Network) at 81 clinical sites. Subjects (N = 289) were randomly assigned CVC 150 mg or placebo. Primary outcome was ≥2-point improvement in NAS and no worsening of fibrosis at year 1. Key secondary outcomes were: resolution of steatohepatitis and no worsening of fibrosis; improvement in fibrosis by ≥1 stag…

0301 basic medicineLiver CirrhosisMalePlacebo-controlled studyMedical Biochemistry and MetabolomicsGastroenterologyOral and gastrointestinallaw.inventionHepatitisNASH NAFLD CVC nonalcoholic fatty liver inflammationSteatohepatitis/Metabolic Liver Disease0302 clinical medicineRandomized controlled trialFibrosislawNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseaseeducation.field_of_studyCVCLiver DiseaseNASHImidazolesMiddle AgedTreatment OutcomeTolerabilityLiverSulfoxides6.1 PharmaceuticalsCCR5 Receptor Antagonists030211 gastroenterology & hepatologyOriginal ArticleFemalePatient SafetyAdultmedicine.medical_specialtyPopulationChronic Liver Disease and CirrhosisClinical Trials and Supportive ActivitiesClinical SciencesImmunologyPlacebo03 medical and health sciencesDouble-Blind MethodClinical ResearchInternal medicineNAFLDmedicinenonalcoholic fatty liverHumanseducationAgedHepatologyGastroenterology & Hepatologybusiness.industryEvaluation of treatments and therapeutic interventionsOriginal Articlesmedicine.diseaseequipment and suppliesSurgeryCVC; NAFLD; NASH; inflammation; nonalcoholic fatty liver030104 developmental biologyinflammationHuman medicineSteatohepatitisbusinessDigestive DiseasesBiomarkers
researchProduct

CD4+ CCR5+ and CD4+ CCR3+ lymphocyte subset and monocyte apoptosis in patients with acute visceral leishmaniasis

2004

The potential involvement of apoptosis in the pathogenesis of visceral leishmaniasis (VL) was examined by studying spontaneous and Leishmania antigen (LAg)-induced apoptosis using cryopreserved peripheral blood mononuclear cells (PBMC) of Sicilian patients with VL. Results indicate that monocytes and T lymphocytes from acute VL patients show a significantly higher level of apoptosis compared with that observed in healed subjects. The percentage of apoptotic cells was higher in monocytes than in T lymphocytes. T cells involved in programmed cell death (PCD) were mainly of the CD4(+) phenotype. In particular, the T helper 1-type (Th1) subset, as evaluated by chemokine receptor-5 (CCR5) expres…

AdultCD4-Positive T-LymphocytesProgrammed cell deathChemokineReceptors CCR5Receptors CCR3ImmunologyAntigens ProtozoanApoptosisCD8-Positive T-LymphocytesBiologyPeripheral blood mononuclear cellMonocytesParacrine signallingAntigenmedicineHumansImmunology and Allergyfas ReceptorAutocrine signallingCells CulturedMonocyteOriginal ArticlesTh1 CellsLymphocyte Subsetsmedicine.anatomical_structureApoptosisAcute DiseaseImmunologyLeukocytes Mononuclearbiology.proteinLeishmaniasis VisceralReceptors ChemokineImmunology
researchProduct

CD52‐negative T cells predict acute graft‐versus‐host disease after an alemtuzumab‐based conditioning regimen

2020

Allogeneic haematopoietic stem cell transplantation (HSCT) after a reduced-intensity conditioning (RIC) regimen with fludarabine, melphalan and alemtuzmab is an effective therapy for haematological malignancies. Alemtuzumab, a monoclonal antibody against CD52, a glycosylphosphatidylinositol-anchor-bound surface protein on lymphocytes, depletes T cells to prevent graft-versus-host disease (GVHD). Despite this, acute and chronic GVHD (a/cGVHD) remain life-threatening complications after HSCT. The aim of the present study was to identify parameters to predict GVHD. In 69 patients after HSCT, T-cell subsets were functionally analysed. Reconstitution of CD52neg T cells and CD52neg regulatory T c…

AdultMaleMelphalanReceptors CXCR3Transplantation ConditioningReceptors CCR5CD52Graft vs Host Diseasechemical and pharmacologic phenomenaCXCR3T-Lymphocytes Regulatory03 medical and health sciences0302 clinical medicineRisk Factorsimmune system diseaseshemic and lymphatic diseasesmedicineHumansAlemtuzumabAgedbusiness.industryHematopoietic Stem Cell TransplantationMembrane ProteinsHematologyMiddle AgedAllograftsFludarabineTransplantationHaematopoiesissurgical procedures operativeCD52 Antigen030220 oncology & carcinogenesisAcute DiseaseImmunologyAlemtuzumabFemaleStem cellbusiness030215 immunologymedicine.drugBritish Journal of Haematology
researchProduct

CC chemokine receptor 5 polymorphism in Italian patients with Beḩet's disease

2012

OBJECTIVE: To evaluate the potential role of CC chemokine receptor 5 (CCR5)Δ32 polymorphism in the susceptibility to and clinical expression of Behcet's disease (BD) in a cohort of Italian patients. METHODS: One hundred and ninety-six consecutive Italian patients satisfying the ISG criteria for BD were followed up for 8 years, and 180 healthy age- and sex-matched blood donors were molecularly genotyped for the CCR5Δ32 polymorphism. A standard microlymphocytotoxicity technique was used to serotype HLA-B51. The patients were subgrouped on the basis of the presence or absence of clinical manifestations. RESULTS: The distribution of the CCR5Δ32 genotype differed between BD patients and controls…

AdultMalemedicine.medical_specialtyHeterozygoteReceptors CCR5Behcet's disease CCR5 polymorphismBehcet's diseaseGastroenterologyRheumatologyGeneticGene FrequencyInternal medicineGenotypeReceptorsMedicineHumansPharmacology (medical)Genetic Predisposition to DiseaseAllelePolymorphismAllele frequencyPolymorphism Geneticbusiness.industryBehcet SyndromeHomozygoteCase-control studyOdds ratiomedicine.diseaseBeḩet's disease; CC chemokine receptor 5 Δ32 olymorphism; Chemokines; Disease manifestations; Adult; Behcet Syndrome; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to Disease; HLA-B Antigens; Heterozygote; Homozygote; Humans; Italy; Male; Polymorphism Genetic; Receptors CCR5; Rheumatology; Pharmacology (medical)Adult; Behcet Syndrome; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to Disease; HLA-B Antigens; Heterozygote; Homozygote; Humans; Italy; Male; Polymorphism Genetic; Receptors CCR5ItalyHLA-B AntigensCase-Control StudiesImmunologyCohortFemalebusinessCC chemokine receptorsCCR5
researchProduct

Natural Proteolytic Processing of Hemofiltrate Cc Chemokine 1 Generates a Potent Cc Chemokine Receptor (Ccr)1 and Ccr5 Agonist with Anti-HIV Properti…

2000

Hemofiltrate CC chemokine (HCC)-1 is a recently described human chemokine that is constitutively expressed in numerous tissues and is present at high concentrations in normal plasma. Using a cell line expressing CC chemokine receptor (CCR)5 as a bioassay, we isolated from human hemofiltrate an HCC-1 variant lacking the first eight amino acids. HCC-1[9–74] was a potent agonist of CCR1, CCR3, and CCR5 and promoted calcium flux and chemotaxis of T lymphoblasts, monocytes, and eosinophils. It also blocked entry of HIV-1 strains using CCR5 as coreceptor. Limited tryptic digestion of HCC-1 generated the active variant. Conditioned media from several tumor cell lines activated HCC-1 with a high ef…

AdultReceptors CCR5Anti-HIV AgentsReceptors CCR3Molecular Sequence DataImmunologyReceptors CCR1C-C chemokine receptor type 6BiologyChemokine receptorEndopeptidasesHumansImmunology and AllergyCCL17Amino Acid SequenceCalcium SignalingCCL15CCL13endopeptidaseChemotactic FactorsHIVBlood ProteinsMolecular biologyPeptide FragmentsChemotaxis LeukocyteBiochemistryChemokines CCCulture Media ConditionedXCL2Biological AssayReceptors ChemokineOriginal ArticleCC chemokine receptorsProtein Processing Post-TranslationalCCL21Journal of Experimental Medicine
researchProduct

CCR5 Receptor: Biologic and Genetic Implications in Age-Related Diseases

2007

The CC chemokine receptor 5 (CCR5) is a member of CC-chemokine receptor family. CCR5 has the characteristic structure of a seven transmembrane G protein-coupled receptor (GPCR), which regulates trafficking and effector functions of memory/effector Th1 cells, macrophages, NK cells, and immature dendritic cells. CCR5 and its ligands are important molecules in viral pathogenesis. CCR5 represents the co-receptor for macrophage (M) and dual (T cell and M)-tropic immunodeficiency viruses. Recent evidence has also demonstrated the role of CCR5 in a variety of human diseases, ranging from infectious and inflammatory diseases to cancer. In this article, we describe the involvement of CCR5 in two age…

AgingChemokineReceptors CCR5Chemokine receptor CCR5virusesT cellViral pathogenesisDiseaseLigandsModels BiologicalGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of Sciencecardiovascular diseaseAlzheimer DiseasemedicineHumansMacrophageSettore MED/04 - Patologia GeneraleInflammationGenomebiologyEffectorMacrophagesGeneral Neurosciencevirus diseasesDendritic CellsAtherosclerosisKiller Cells Naturalmedicine.anatomical_structureCardiovascular DiseasesImmunologybiology.proteinMicrogliaCC chemokine receptorsAlzheimer’s diseaseCCR5Gene DeletionAnnals of the New York Academy of Sciences
researchProduct

Expression of chemokine receptor CXCR3, CXCR4, and CXCR7 and their respective ligands in rhabdomyosarcoma

2010

CCR1Cancer ResearchCCR2biologyChemokine receptor CCR5C-C chemokine receptor type 7C-C chemokine receptor type 6Chemokine receptorGeneticsbiology.proteinCancer researchXCL2Molecular BiologyCCL21Cancer Genetics and Cytogenetics
researchProduct

Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction.

2005

CD8+ T cells have a crucial role in resistance to pathogens and can kill malignant cells; however, some critical functions of these lymphocytes depend on helper activity provided by a distinct population of CD4+ T cells. Cooperation between these lymphocyte subsets involves recognition of antigens co-presented by the same dendritic cell, but the frequencies of such antigen-bearing cells early in an infection and of the relevant naive T cells are both low. This suggests that an active mechanism facilitates the necessary cell-cell associations. Here we demonstrate that after immunization but before antigen recognition, naive CD8+ T cells in immunogen-draining lymph nodes upregulate the chemok…

CD4-Positive T-LymphocytesReceptors CCR5T cellAntigen presentationCell CommunicationBiologyCD8-Positive T-LymphocytesLymphocyte ActivationInterleukin 21MiceCell MovementmedicineCell AdhesionCytotoxic T cellAnimalsAntigen-presenting cellChemokine CCL4Chemokine CCL3MultidisciplinaryCD28Dendritic cellDendritic CellsMacrophage Inflammatory ProteinsNatural killer T cellmedicine.anatomical_structureChemokines CCImmunologyLymph NodesChemokinesImmunologic MemoryNature
researchProduct

Effect of female genital schistosomiasis and anti-schistosomal treatment on monocytes, CD4+ T-cells and CCR5 expression in the female genital tract

2014

Published version of an article from the journal: PLoS One. Also available from the publisher: http://dx.doi.org/10.1371/journal.pone.0098593 BACKGROUND: Schistosoma haematobium is a waterborne parasite that may cause female genital schistosomiasis (FGS), characterized by genital mucosal lesions. There is clinical and epidemiological evidence for a relationship between FGS and HIV. We investigated the impact of FGS on HIV target cell density and expression of the HIV co-receptor CCR5 in blood and cervical cytobrush samples. Furthermore we evaluated the effect of anti-schistosomal treatment on these cell populations. DESIGN: The study followed a case-control design with post treatment follow…

CD4-Positive T-LymphocytesViral DiseasesGynecologic InfectionsVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Tropical medicine: 761Gene Expressionlcsh:MedicineGlobal HealthMonocytesPraziquantelWhite Blood CellsImmunodeficiency VirusesAnimal CellsMedicine and Health SciencesSchistosomiasisPublic and Occupational Healthlcsh:ScienceT CellsCoinfectionObstetrics and GynecologyGenitalia FemaleAIDSInfectious DiseasesPhenotypeMedical MicrobiologyHelminth InfectionsViral PathogensSchistosoma haematobiumFemaleCellular TypesResearch ArticleNeglected Tropical DiseasesAdultAdolescentReceptors CCR5Immune CellsUrologyImmunologySexually Transmitted DiseasesMicrobiologyImmunophenotypingYoung AdultParasitic DiseasesAnimalsHumansMicrobial PathogensBlood CellsGenitourinary Infectionslcsh:RBiology and Life SciencesHIVCell BiologyTropical DiseasesCase-Control StudiesWomen's HealthClinical Immunologylcsh:QGenital Diseases Female
researchProduct

Pharmacogenomics: a tool to prevent and cure coronary heart disease.

2007

Inflammation and genetics play an important role in the pathogenesis of coronary heart disease (CHD). This is supported by epidemiological studies which have thoroughly investigated the association between CHD and gene polymorphisms of the inflammatory molecules. Moreover, efforts to find elective therapy have not been rewarding and, despite the increasing appreciation of the role of genetics in CHD and myocardial infarction (MI) pathogenesis, pharmacogenomic approaches to uncover drug target have not been extensively explored. A critical search of published literature has suggested few inflammatory genes directly involved in the risk to develop CHD and MI. The selected genes are, the pro- …

Candidate genepharmacogenomicLipoxygenaseLipopolysaccharide ReceptorsMyocardial InfarctionCoronary DiseaseDiseaseBioinformaticsRisk AssessmentPathogenesisRisk FactorsDrug DiscoverymedicinecytokineHumansGenetic Predisposition to DiseaseMyocardial infarctionTLR4PharmacologyInflammationPolymorphism Geneticbusiness.industryPatient SelectionCase-control studyCOXLOXmedicine.diseaseAtherosclerosisToll-Like Receptor 4Treatment OutcomePharmacogeneticsProstaglandin-Endoperoxide SynthasesPharmacogenomicsCase-Control StudiesImmunologyCytokinesReceptors ChemokineChemokinesbusinessRisk assessmentCD14CCR5PharmacogeneticsCurrent pharmaceutical design
researchProduct